To investigate whether all patients in need of an allogeneic hematopoietic SCT (HSCT) are offered one, we retrospectively investigated the policy for all children diagnosed with myelodysplastic syndrome (n ¼ 90) or relapsed AML (n ¼ 75) between 1998 and 2008. These children are registered at diagnosis and treated according to protocols of the Dutch Childhood Oncology Group, which provides accurate disease incidence data and protocol-indicated appropriateness for HSCT. For 48 (30%) patients, a family donor was identified; for 90 (57%) patients, an unrelated donor (UD) search was performed; and for 21 (13%) patients, no UD search was initiated. Reasons for not initiating an UD search include: progressive disease (n ¼ 10), conserve quality of life (n ¼ 1), stable disease (n ¼ 3), immunosuppressive therapy (n ¼ 2), patient death (n ¼ 3), patient lives abroad (n ¼ 1) and second relapse (n ¼ 1). On the basis of the time interval between date of diagnosis and date of death/last follow-up, for eight (5%) patients, it may be questioned why an UD search was not performed. The fact that 95% of all children are given the option of an allogeneic HSCT is encouraging and reasons not to transplant seem fair in most cases.
Introduction
In the Netherlands, all children with malignancies are registered at diagnosis and treated according to protocols of the Dutch Childhood Oncology Group (DCOG). 1 Children with myelodysplastic syndrome (MDS) and AML in first relapse are considered candidates for allogeneic hematopoietic SCT (HSCT) as described in the DCOG treatment protocols. (http://clinicaltrials.gov/ct2/ show/NCT00662090?term ¼ ewog+mds+2006&rank ¼ 1. http://clinicaltrials.gov/ct2/show/NCT00186966?term ¼ chi ldren+relapsed+refractory+AML&rank ¼ 3.) This provides a unique opportunity to investigate whether allogeneic HSCT is offered as a therapy to all children in the Netherlands, as accurate disease incidence data and protocol-indicated appropriateness for HSCT are available. Although allogeneic HSCT is considered a curative therapy for several childhood hematopoietic malignant diseases, 2 the presumption exists that not all patients in need of an allogeneic HSCT are offered one. [3] [4] [5] [6] [7] Despite the use of treatment protocols and specific guidelines for allogeneic HSCT, there may be a number of reasons for patients not receiving allogeneic HSCT. First of all, the most important requirement for a successful allogeneic HSCT is the availability of a suitable donor, ideally an HLA identical family donor (FD). Unfortunately, for approximately 25% of the patients, such a donor is available. Consequently, most patients have to rely on other donor types, including non-identical FDs, unrelated donors (UD) and cord blood units. For approximately 80-90% of (Northwest European) patients who lack an identical sibling donor, an UD is identified. 8, 9 Furthermore, it has been shown that of all patients for whom an UD search was initiated, a significant group is not transplanted. 5, 8 Not the duration of the search process itself or the availability of a suitable donor, but the worsening clinical condition of the patient during the search process is the main cause for this low transplantation rate. 5, 8 Barriers for access to an allogeneic HSCT include physician characteristics or preferences, 10, 11 socioeconomic factors and access to the healthcare system or transplantation centers, 4, 5, [12] [13] [14] [15] and type of hospital or transplant center. 11, 16 Potential causes for lack of access to allogeneic HSCT may be due to discussion on the efficiency of allogeneic HSCT vs chemotherapy or autologous HSCT, and whether to transplant in first or second CR. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Lack of consensus on the best indication(s) for allogeneic HSCT remains a problem, as it is methodologically difficult to evaluate the advantage of allogeneic HSCT over chemotherapy or autologous HSCT. 30, 31 The main reasons for this debate are the high treatment-related mortality, 18, 23, 32, 33 adverse late effects and worse quality of life associated with allogeneic HSCT. 20, 34, 35 Especially allogeneic HSCT with an UD remains somewhat controversial for a large part of patients and is therefore advised to be performed in the context of clinical trials. 17 For certain high-risk disease patients or patients whose disease relapsed and who lack an identical FD, allogeneic HSCT with an UD is indicated. 29, [36] [37] [38] In all these studies, only patients for whom an UD search was performed were included. As a consequence, a large number of patients who are appropriate candidates for an allogeneic HSCT might have been omitted from the study population. In addition, hypothetical and/or incomplete disease incidence data were used. The aim of the present study is to investigate whether appropriate pediatric patients in the Netherlands are given the opportunity of an allogeneic HSCT, and if not, to identify possible reasons and solutions.
Patients and methods

Dutch Childhood Oncology Group (DCOG)
The DCOG was founded in 2002 and evolved from the Working group Leukemia in Children, which was established in 1972. The activities of the DCOG are more extensive than those of the Working group and cover not only children with leukemia and lymphoma, but focus on all cancers in pediatric patients. The DCOG is a nationwide partnership, where pediatric oncologists and other professionals in this area work closely together, which aims to provide the best available treatment to the child and his parents.
Protocols and HSCT indication
All children (o18 years of age) were treated according to DCOG treatment protocols. The MDS protocols are developed in collaboration with the European Working Group of MDS (EWOG-MDS) and juvenile myelomonocytic leukemia in childhood. These studies are conducted in accordance with the Declaration of Helsinki and all patients' caretakers signed written informed consent forms before enrollment.
EWOG-MDS-1998: 39 allogeneic HSCT is the treatment of choice for children with all disease classification types, if a compatible FD or UD is available.
Relapsed AML 2001/01 (online access via http:// clinicaltrials.gov/ct2/show/NCT00186966?term ¼ children+ relapsed+refractory+AML&rank ¼ 3): patients in CR after two courses of reinduction chemotherapy are eligible for allogeneic HSCT. For both low risk (late first relapse (X 1 year from initial diagnosis)) and high-risk disease (early first relapse (o1 year from initial diagnosis), multiple relapse or refractory disease), HSCT with a compatible FD or UD is indicated. Irrespective of disease risk, an allogeneic HSCT should be avoided within 12 months after a previous allogeneic HSCT.
EWOG-MDS-2006 (online access via http://clinicaltrials.gov/ ct2/show/NCT00662090?term ¼ ewog+mds+2006&rank ¼ 1): Therapy options for MDS depend on disease classification type and are therefore diverse. However, in most cases, the only potential curative therapy is allogeneic HSCT with either a compatible FD or UD. Patients with refractory cytopenia or refractory anemia have several options before the need for an allogeneic HSCT, including 'wait-and-see' approach, transfusion therapy and immunosuppressive therapy. Patients with high-risk MDS (RAEB and RAEB-T) and juvenile myelomonocytic leukemia should be transplanted as soon as possible.
Study population
All children in the Netherlands, diagnosed with primary MDS (n ¼ 90) or AML in first relapse (n ¼ 75) between 1998 and 2008, were included in this retrospective study. Six patients were excluded from analysis, as they were rightly excluded from HSCT, according to the protocol or advice from the protocol chairs. Two of these patients were not eligible for protocol treatment according to exclusion criteria described in the protocols; one MDS patient had Down's syndrome and one relapsed AML patient was diagnosed with FAB type M3. Four AML patients relapsed within 12 months after they were transplanted in first CR and therefore, were not considered appropriate candidates for a second allogeneic HSCT. Consequently, 159 patients were analyzed.
Statistics
To characterize the patients who did not have access to allogeneic HSCT, we divided the study population into three patient groups: patients who had a FD, patients for whom an UD search was performed, and patients for whom no UD search was performed. We investigated gender (male/female), diagnosis (MDS/relapsed AML), age at diagnosis (continuous), year of diagnosis (continuous), being alive at last follow-up (yes/no) and cause of death (discrete) for differences between the three patient groups. Differences in discrete variables are examined with Pearson's w 2 -test or Fisher's exact test, and differences in continuous variables with the Kruskal-Wallis test or Mann-Whitney test. Furthermore, we looked into the reasons for not performing an UD search with the patients' corresponding survival interval to determine if the reasons could be considered questionable or not. For MDS patients, the variables 'survival interval' and 'HSCT interval' were defined as the number of days from diagnosis until death/last follow-up and HSCT, respectively. For relapsed AML patients, the variables 'survival interval' and 'HSCT interval' were defined as the number of days from diagnosis of first relapse until death/last follow-up and HSCT, respectively. Relapse interval was defined as the number of days from diagnosis of AML to diagnosis of first relapse of the disease. Two-sided P-values p0.050 were considered statistically significant and all analyses were performed using SPSS 17.0 for Windows.
Results
The study population consists of 159 children, 89 MDS patients and 70 patients with relapsed AML. For 48 (30%) patients, a FD was identified (including non-identical FD); for 90 (57%) patients, an UD search was performed; and for 21 (13%) patients, no UD search was initiated (Figure 1 ). Patient and HSCT characteristics are shown in Table 1 . There are no differences in sex, diagnosis, year of diagnosis, relapse interval, being alive at last follow-up and cause of death between the three patient groups. Patients for whom no UD search was performed are, on average, younger at diagnosis than patients with a FD or patients for whom an UD search was performed (2.4 vs 8.5 years; P-value ¼ 0.018). Of the patients with a FD, 85% (n ¼ 41) received a transplant, and of the patients for whom an UD search was performed, 74 (82%) received a transplant. The majority of patients were transplanted with an identical FD (n ¼ 31 (76%)) or a 10/10 matched-UD; n ¼ 53 (72%)). Seventy-eight (68%) patients received a BM graft. For patients transplanted with a FD, the median interval from diagnosis to HSCT was 116 days and 75% was transplanted within 176 days. For patients transplanted with an UD, the median interval from diagnosis to HSCT was 139 days and 75% was transplanted within 185 days. As patients with a FD and patients for whom an UD search was performed will have to be alive up to that point, they, on average, live longer than patients without UD search (630 vs 511 vs 107 days, respectively; P-value ¼ 0.000). The 21 patients for whom no UD search was initiated were divided into patients with and without access to allogeneic HSCT according to the reasons not to perform an UD search, which are listed in Table 2 . For relapsed AML patients, the predominant reason not to perform an UD search was death in progressive disease (n ¼ 10 (6.3%)). Four of them died, on average, 1 month after diagnosis of the first relapse (median (range) ¼ 31 (7-49) days). The other six patients lived long enough after first relapse (median (range) ¼ 103 (63-123) days) to have had an UD search performed for them. The fact that these patients were not in CR should not have prevented an UD search. Three patients died within 41 days after diagnosis of MDS. The possibility of allogeneic HSCT was discussed with all three patients; however, they died before an UD search was initiated. For five patients, diagnosed with MDS refractory cytopenia or MDS refractory anemia, other treatment Access to allogeneic hematopoietic SCT MM Jöris et al options were chosen instead of allogeneic HSCT, in accordance with the treatment protocol. Three patients had stable disease and the 'wait-and-see' approach was applied; the other two were treated with immunosuppressive therapy. Finally, one relapsed AML patient had a second relapse before an UD search was performed; however, the interval between first and second relapse was long enough to initiate an UD search (73 days). Altogether, for eight (5%) patients, it is questionable that an UD search was not performed. 
Discussion
This study investigated access to allogeneic HSCT for children in the Netherlands. The results show that in this population with poor prognosis for most patients, the indication for allogeneic HSCT is clear. For eight (5%) patients, it is questionable that an UD search was not performed. Poor clinical condition may have been the reason to omit the search, and one could argue what is the optimal moment to initiate an UD search; but strictly looking at the time intervals regardless of whatever happened to the patient in a later time point, these eight patients should have had access to an allogeneic HSCT. The fact that most children are given an allogeneic HSCT is encouraging and reasons not to transplant seem fair in most cases. These Dutch results are in contrast with transplant rates reported in the USA, where patients who were diagnosed with diseases potentially treatable with allogeneic HSCT, only an estimated 17% would theoretically undergo one. 5 Probably this percentage is even lower, as some of these patients may not need a transplant and can be treated with other therapies. However, there are some major differences with our study. First, the American study included both pediatric and adult patients with a wide variety of diseases, whereas we only included children with MDS and relapsed AML. Second, in the USA, approximately 11% of the children and 15% of the adults were uninsured and therefore did not have full access to health care and allogeneic HSCT, whereas in the Netherlands, everyone is required to have health insurance. Third, the probabilities of receiving an allogeneic HSCT reported in the American paper are partly speculative because of incomplete disease incidence data and the assumption of universal donor availability. Furthermore, the Netherlands is a small country and all Dutch children with malignancies are treated according to DCOG protocols, leaving less room for discussion on which therapy would be most effective. Also because these are pediatric patients, clinicians may be more inclined to follow protocol. Together, this may result in a higher transplantation rate. In contrast to the role of allogeneic HSCT in patients with MDS, where there is only no consensus on using an AML-like induction before allogeneic HSCT, [40] [41] [42] the indication for allogeneic HSCT is less clear in patients with primary AML and ALL. The usage of allogeneic HSCT in those patients is limited by consideration of the risk-benefit ratio, especially because allogeneic HSCT implies a significant risk for treatment-related mortality. Furthermore, the response rate to chemotherapy in children with AML in first CR and especially in children with ALL in first CR is reasonable to excellent. 21 The influence of physician preferences in following protocol treatment or choosing allogeneic HSCT over other less aggressive therapies in some cases remains unknown. Recently a trend towards reduced treatment-related mortality 33, 43 and a decreased incidence of aGVHD 44 after allogeneic HSCT was seen. This may indicate that the efficiency of HSCT is improving over time, which should motivate the development of new treatment protocols by which physicians are encouraged to refer patients in early stages of their high-risk disease to experienced transplant centers for consultation. Furthermore, non-identical UD 45, 46 or cord blood units 47 may be included more often as potential donor options in current protocols, based on the encouraging results reported so far. Therefore, the lack of an identical FD or a 10/10 matched-UD should not discourage referral and/or delay the use of HSCT when indicated. Moreover, the main advantage of using a cord blood units compared with an UD is the shorter search interval and faster availability. 48 So in cases where the UD search might take too long or the patient is at high risk of relapsing, transplantation of a cord blood unit might decrease the probability of deterioration of the patients' clinical condition. In conclusion, the transplantation rate in the Netherlands for children diagnosed with primary MDS or relapsed AML is relatively high, and due to recent developments, it may even increase in the future as predicted by the European Group for Blood and Marrow Transplantation. 12 Whether this holds true for other malignancies or adult patients remains to be determined and is the subject of future studies.
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